ClinicalTrials.gg

Program

RAS Inhibitor AN9025

Its studies are led by Adlai Nortye Biopharma.

Furthest: phase 1, since Nov 14, 20251 company-led study, 1 open or runningNext primary completion: Jan 31, 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Adlai Nortye Biopharma11 open or runningphase 1since Nov 14, 2025Nov 14, 2025Jan 31, 2028phase 1 · NCT07252479

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 14, 2025First study: phase 1 study in Solid Tumors (Phase 1)First studyNCT07252479 · 118 planned · United States

Ahead

  1. Jan 31, 2028Primary completion: phase 1 study in Solid Tumors (Phase 1)NCT07252479

TargetBeta

KRAS →NRAS →read by rule
“An orally bioavailable inhibitor of the active, guanosine triphosphate (GTP)-bound form of both wild type and mutant variants of the RAS isoforms, including NRAS and KRAS, ”NCIt, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
daraxonrasibruleRevolution Medicinesphase 310

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07252479Solid Tumors (Phase 1) · United States1RecruitingJan 31, 2028118

How it is read

Names in the registry

  • “AN9025 oral capsule”, 1 entry

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.